000			04029nam a22004214a 4500
001			EBC3420325
003			MiAaPQ
006			m o d |
007			cr cn|||||||||
008			010517s2002 ctua sb 101 0 eng
010			_z 2001039022
020			_z0300087519 (cloth : alk. paper)
035			_a(MiAaPQ)EBC3420325
035			_a(Au-PeEL)EBL3420325
035			_a(CaPaEBR)ebr10210208
035			_a(CaONFJC)MIL172161
035			_a(OCoLC)923592091
040			_aMiAaPQ _cMiAaPQ _dMiAaPQ
050		4	_aRA643.8 _b.Q36 2002
082	0	4	_a362.1/969792 _221
245	0	0	_aQuantitative evaluation of HIV prevention programs _h[electronic resource] / _cedited by Edward H. Kaplan and Ron Brookmeyer.
260			_aNew Haven : _bYale University Press, _cc2002.
300			_ax, 335 p. : _bill.
490	1		_aThe Yale ISPS series
500			_aProceedings of a conference sponsored by the Societal Institute of the Mathematical Sciences (the 14th in a series of research application conferences begun in 1974) held in July, 1998, in Divonne-les-Bains, France.
504			_aIncludes bibliographical references and index.
505	8		_aMachine generated contents note: Part I: Evaluating HIV Prevention Programs: Context and Concepts -- Chapter 1. Overview of HIV Prevention Programs in Developing Countries Michael H. Merson andJulia M. Dayton 13 -- Chapter 2. Implications of Economic Evaluations for National HIV Prevention Policy Makers David R. Holtgrave -- and Steven D. Pinkerton 32 -- Chapter 3. Statistical Issues in HIV Prevention Ron Brookmeyer 55 -- Chapter 4. Epidemiological Issues in the Evaluation of HIV Prevention Programs Nancy S. Padian and Stephen C. Shiboski 79 -- Part II: Cost-Effectiveness and Resource Allocation -- Chapter 5. Difficult Choices, Urgent Needs: Optimal Investment in HIV Prevention Programs Margaret L. Brandeau 97 Chapter 6. Methadone Treatment as HIV Prevention: Cost-EffectivenessAnalysis Harold Pollack 118 -- Chapter 7. Costs and Benefits of Imperfect HIV Vaccines: Implications for Vaccine Development and Use Douglas K Owens, Donna M. Edwards, and Ross D. Shachter 143 -- Part III: Case Studies -- Chapter 8. Harm Reduction in Rome: A Model-Based Evaluation of Its Impact on the HIV-1 Epidemic MassimoArca, Teresa Spadea, Giulia Cesaroni, Marina Davoli, Annette D. Verster, and Carlo A. Perucci 175 -- Chapter 9. Evaluating Israel's Ethiopian Blood Ban EdwardH. Kaplan 189 -- Chapter 10. Feeding Strategies for Children of HIV-Infected Mothers: Modeling the Trade-Off Between HIV Infection and Non-HIV Mortality James G. Kahn, ElliotMarseille, and Joseph Saba 202 -- Part IV: New Methods for New Problems -- Chapter 11. Design of HIVTrials for Estimating External Effects Tomas Philipson 223 -- Chapter 12. Estimation of Vaccine Efficacy for Prophylactic HIV Vaccines Ira M Longini, Jr., Michael G. Hudgens, and M. Elizabeth Halloran 241 -- Chapter 13. Health Policy Modeling: Epidemic Control, HIVVaccines, and -- Risky Behavior Sally Blower, Katia Koelle,and John Mills 260 -- Chapter 14. Development and Validation of a Serologic Testing Algorithm for Recent HIV Seroconversion GlenA. Satten, -- Robert S. Janssen, Susan Stramer, and Michael P Busch 290 -- Chapter 15. Issues in Quantitative Evaluation of Epidemiologic Evidence for Temporal Variability of HIV Infectivity Stephen C. Shiboski and Nancy S. -- Padian 305.
533			_aElectronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.
650		0	_aAIDS (Disease) _xPrevention _vCongresses.
650		0	_aAIDS (Disease) _xPrevention _xGovernment policy _xEvaluation _vCongresses.
655		4	_aElectronic books.
700	1		_aKaplan, Edward Harris.
700	1		_aBrookmeyer, Ron.
710	2		_aSIAM Institute for Mathematics and Society.
710	2		_aProQuest (Firm)
830		0	_aYale ISPS series.
856	4	0	_uhttps://ebookcentral.proquest.com/lib/nird-ebooks/detail.action?docID=3420325 _zClick to View
999			_c40420 _d40420